Oxford, UK – July 2, 2025 – U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded Best Pitch at the 2025 BioEscalator Pitch Battle, held at Oxford’s leading life sciences innovation hub. The event, sponsored by Oxford North, brought together high-growth biotech and healthtech ventures to compete in a showcase of scientific vision, commercial strategy, and founder storytelling.

U‑Ploid’s pitch stood out among a competitive field of early-stage companies, including those backed by international accelerators and working on next-generation cancer therapies, antimicrobial resistance, and platform technologies. The judging panel, comprising experienced investors and exited founders, praised U‑Ploid for its clear articulation of a significant unmet need, its innovative approach to reproductive ageing, and the quality of its translational and regulatory roadmap.

“We’re honoured to receive this recognition from the BioEscalator community,” said Dr Jordan Abdi, Co-founder & CEO of U‑Ploid. “It reflects not only the strength of our science, but also the scale of the problem we are tackling. Millions of people face age related infertility, and we believe a new generation of egg-quality therapeutics can transform the standard of care.”

U‑Ploid is developing a first-in-class programme targeting meiotic aneuploidy, the leading cause of failed conception in women over 35. Unlike traditional fertility approaches that focus on embryo selection, U‑Ploid addresses the biological root of the problem: the age-related decline in oocyte quality. Its work builds on recent advances in reproductive biology and is guided by a growing network of clinical and scientific collaborators across Europe and the US.

The annual Pitch Battle, now in its sixth year, is a flagship event in Oxford’s innovation calendar. This year’s judging panel included representatives from BGF, Longwall Ventures, and Bioarchitech, alongside leading voices in UK biotech investment. The event underscores the strength of Oxford’s startup ecosystem and its role in nurturing the next wave of category-defining life science companies.

‍About U-Ploid Biotechnologies

U-Ploid is a biotechnology company developing next-generation fertility therapeutics to address the global challenge of age-related infertility. Co-founded by Jordan Abdi, Chloe Charalambous, and Alexandre Webster, U-Ploid is pioneering innovative solutions to improve IVF outcomes and expand the window of reproductive opportunity. The company's technology is designed to increase the quality of older eggs, restoring their potential to support healthy pregnancies. U-Ploid is committed to improving access to fertility care and envisions a future where anyone who wants to start a family, can. For more information, go to u-ploid.com or follow us on LinkedIn.

Press and Investor Contact

press@u-ploid.com